Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 8,763 Shares
Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 8,763 shares of Boston Scientific stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $27.74, for a total value of $243,085.62. Following the sale, the senior vice president now owns 24,201 shares of the company’s stock, valued at $671,335.74. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Boston Scientific Corporation (BSX) traded down $0.09 during mid-day trading on Thursday, hitting $27.43. The company had a trading volume of 8,963,380 shares, compared to its average volume of 12,170,000. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a 1-year low of $22.94 and a 1-year high of $29.93. The company has a market cap of $37,670.00, a P/E ratio of 44.97, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business earned $0.27 EPS. sell-side analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of BSX. Janus Henderson Group PLC increased its position in Boston Scientific by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares during the period. BlackRock Inc. increased its position in Boston Scientific by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares during the period. Prudential Financial Inc. increased its position in Boston Scientific by 149.1% in the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares during the period. Vanguard Group Inc. increased its position in Boston Scientific by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after buying an additional 2,522,556 shares during the period. Finally, American Century Companies Inc. increased its position in Boston Scientific by 28.9% in the 3rd quarter. American Century Companies Inc. now owns 10,496,489 shares of the medical equipment provider’s stock worth $306,183,000 after buying an additional 2,352,297 shares during the period. 90.36% of the stock is currently owned by institutional investors.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.